Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Aug. 13, 2026	Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa（PDF/137KB）	R&D
Aug. 12, 2026	Regarding a Report Concerning Sumitomo Pharma (The Company's Views on “Sumitomo Chemical and Sumitomo Pharmaceutical: Part II - CiRA, Dr. Yamanaka, and the undisclosed history of image duplication concerns”)	Others
Aug. 07, 2026	Additional Explanation Regarding the Report “Sumitomo Chemical and Sumitomo Pharmaceutical: The ¥116 billion Swiss Shuffle”	Others
Aug. 04, 2026	Sumitomo Pharma Contributes to Relief Efforts for the 2026 Kumamoto Earthquake	Others
Aug. 04, 2026	Regarding a Report Concerning Sumitomo Pharma	Others
Aug. 03, 2026	Posted Conference on Q1 FY2026 Financial Results [Webcast]	Finances

Oct. 30, 2026	2nd Quarter of FY2026 financial results announcement (scheduled to be disclosed at 3:30 p.m.), conference on 2nd quarter FY2026 financial results for Analysts, Investors, and the Press